智通财经APP讯,银诺医药-B(02591)发布公告,于2025年8月25日,公司已在澳大利亚完成依苏帕格鲁肽α用于治疗肥胖和超重的II期临床试验的首例患者给药。公司预期该临床试验将有约200名参与者入选。
智通财经APP讯,银诺医药-B(02591)发布公告,于2025年8月25日,公司已在澳大利亚完成依苏帕格鲁肽α用于治疗肥胖和超重的II期临床试验的首例患者给药。公司预期该临床试验将有约200名参与者入选。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.